Categories
Change Password!
Reset Password!
Individuals battling ankylosing spondylitis can resort to IL-17 inhibitor therapies for renewed freedom of movement and to reclaim aspects of life that seemed lost to stiffness and pain.
A new comprehensive review after analyzing 50 high-quality studies spanning two decades, confirmed that interleukin (IL)-17 blockers not only reduce spinal inflammation and pain but also dramatically enhance quality of life of patients with ankylosing spondylitis (AS).
Studies from 2000 to 2025 that examined the long-term safety and effectiveness of IL-17 inhibitors in treating AS were considered. Alyssa L. Sepulveda and colleagues analyzed fifty relevant studies from an initial pool of 205, focusing on high-quality trials and excluding unrelated or data-lacking articles.
IL-17 inhibitors—secukinumab, ixekizumab, and netakimab—demonstrated sustained safety and effectiveness in the long-term management of AS. Trials reported ASAS40 response rates of 52%–60.5% by week 16, with over 60% maintaining improvement in disease activity and quality of life over 1 to 5 years. More than 93% of patients demonstrated no structural impairment advancement after two years.
Beyond effectiveness, safety remained consistent: most side effects were mild and manageable, such as minor infections or local injection reactions. Serious complications were rare. Economic analyses identified netakimab as the most cost-effective option. For those battling severe, stubborn inflammation and the looming threat of spinal fusion, IL-17 inhibitors may soon become the benchmark for reclaiming mobility and long-term health.
Research Symposium
Long-term Safety and Comparative Efficacy of IL-17 Inhibitors in Treating Ankylosing Spondylitis
Alyssa L. Sepulveda et al.
Comments (0)